GLP-1 Pipeline Update: November 2026

As the GLP-1 pipeline continues to grow, Prime Therapeutics actively monitors the emerging landscape and provides a credible clinical snapshot of what is on the horizon. The below table displays the earliest potential approval dates for the agents listed. Dates are based on manufacturer-published announcements or communications — or are estimated based on study completion dates — and may change as more information becomes available.

	Diabetes + diabetes-related conditions			Obesity or overweight + related conditions							Other
Drug/Dosage form	**T2DM**	**T2DM + MACE risk reduction**	**Diabetic nephropathy**	**Obesity or overweight**	**Obesity or overweight + MACE risk reduction**	**CLBP + obesity or overweight**	**HTN + obesity or overweight**	**OA of knee + obesity or overweight**	**OSA + obesity or overweight**	**T1DM ± obesity or overweight**	**MASH**
Amgen											
maridebart cafraglutide/SC				2028							
AstraZeneca											
exenatide (Bydureon BCise)/SC	FDA-approved (≥10 years of age)										
exenatide (generic for Byetta)*/SC	FDA-approved (≥10 years of age)										
Eli Lilly											
dulaglutide (Trulicity)/SC	FDA-approved (≥10 years of age)	FDA-approved									
tirzepatide (Mounjaro)/SC	FDA-approved (≥10 years of age)	FDA-approved								2028	
tirzepatide (Zepbound)/SC				FDA-approved					FDA-approved		
orforglipron (Foundayo)/oral	*FDA decision Q4 2026*			FDA-approved			2028		2027		
retatrutide/SC	2028			2028		2028		2028	2028		
Novo Nordisk											
liraglutide (Victoza)*/SC	FDA-approved (≥10 years of age)	FDA-approved									
liraglutide (Saxenda)/SC				FDA-approved (≥12 years of age)							
liraglutide + insulin degludec (Xultophy)/SC	FDA-approved (≥10 years of age)										
semaglutide (Ozempic) 1.5 mg, 4 mg & 9 mg/oral	FDA-approved (≥10 years of age)	FDA-approved									
semaglutide (Rybelsus) 3 mg, 7 mg & 14 mg/oral	FDA-approved (≥10 years of age)	FDA-approved									
semaglutide 25 mg (Ozempic)/oral	*FDA decision Q4 2026*										
semaglutide 1 mg & 2 mg (Ozempic)/SC	FDA-approved (≥10 years of age)	FDA-approved	FDA-approved								
semaglutide 1.5 mg, 4 mg & 9 mg (Wegovy)/oral				FDA-approved (≥12 years of age)	FDA-approved						
semaglutide 25 mg (Wegovy)/oral				FDA-approved	FDA-approved						*FDA decision H1 2027*
semaglutide 1.7 mg & 2.4 mg (Wegovy)/SC				FDA-approved (≥12 years of age)	FDA-approved						FDA-approved
semaglutide 7.2 mg (Wegovy HD)/SC				FDA-approved							
cagrilintide + semaglutide/SC	2028			*FDA decision December 2026*							
Sanofi											
lixisenatide + insulin glargine (Soliqua)/SC	FDA-approved										
Viking											
VK2735/SC				2028							
Zealand, Boehringer Ingelheim											
survodutide/SC				2028	2028						2028 (+ obesity)

*generics available

Glossary

CLBP = chronic low back pain
CV = cardiovascular
FDA = Food and Drug Administration
GLP-1 = glucagon-like peptide-1 receptor agonist medication
HTN = hypertension
MACE = major adverse cardiovascular events
MASH = metabolic dysfunction-associated steatohepatitis
OA = osteoarthritis
OSA = obstructive sleep apnea
SC = subcutaneous
T1DM = type 1 diabetes mellitus
T2DM = type 2 diabetes mellitus

Disclaimer

The drug pipeline is fluid; the dates and information within this publication are subject to change. Nothing herein is or shall be construed as a promise or representation regarding past or future events and Prime Therapeutics expressly disclaims any and all liability relating to the use of or reliance on the information contained in this presentation. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to or disclosed to others at any time without the prior written consent of Prime Therapeutics.

All brand names are property of their respective owners.